Oncology Central

Emerging methods for disease monitoring in malignant gliomas

0

MRI remains the backbone of measuring disease burden and treatment response in individuals with malignant gliomas. Traditional radiographic approaches, however, are largely limited to depicting anatomic changes and are not a direct measure of disease burden. For example, contrast enhancement is related to blood–brain barrier integrity rather than actual tumor size. 

To view restricted content, please:
Share:

Leave A Comment